Jun 18, 2026
Cara Altimus, the CEO of BD², and Emily Baxi, the Program Director of BD²'s Integrated Network, are focused on integrating research and clinical care to improve outcomes for people with bipolar disorder. They emphasize the gaps in diagnostics and effective treatments and the need to collect comprehensive biological...
Jun 18, 2026
Cara Altimus, the CEO of BD², and Emily Baxi, the Program Director of BD²'s Integrated Network, are focused on integrating research and clinical care to improve outcomes for people with bipolar disorder. They emphasize the gaps in diagnostics and effective treatments and the need to collect comprehensive biological...
Jun 9, 2026
Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and...
Jun 9, 2026
Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and...
Jan 22, 2026
Dr. Josh Eloge, Associate Director for the Woman's Board Treatment Research Center, Assistant Professor of Psychiatry and Behavioral Sciences at the Rush University Medical Center, and Founder of Connected Neuroscience has a focus on treatment-resistant depression which is defined as depression that is not relieved by...